Using AI to study multiple sclerosis care records from several centers
Looks at past patient records to build AI tools for multiple sclerosis outlook.
Plain-language title generated from the registry record
Registry title: Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Key facts
- Where
- Berlin and Bochum, GermanySee the 2 sites
Where in Germany
- ERC Charité - Universitätsmedizin BerlinBerlin, GermanyTaking people
- Katholisches Klinikum Bochum - St. Joseph-HospitalBochum, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- icometrix
- Trial code
- NCT06280755
- Record updated
- 12 December 2025
- Original description
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to develop the tools to monitor this progression.Read full original descriptionShow less
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to develop the tools to monitor this progression.
Inclusion: Patients must have a confirmed diagnosis of MS, NMOSD, MOGAD, CIS or RIS; Patient (or patient's legal representative) has previously signed and dated an informed consent form (ICF) for the secondary use of their data, or assent form. Alternatively, the secondary use of the patient's data is allowed following Institutional Review Board (IRB)/Ethical Committee (EC) approval in accordance with national and local subject privacy regulations.
Exclusion: Patients under 18 years of age will be excluded; Other unspecified reasons that, in the opinion of the Investigator or Joint Steering Committee, make the patient unsuitable for participation in the study.